Share Your Story | Foundation For Women’s Cancer
Your voice and words have power—the power of showing people that they’re not alone and the power of increasing awareness, education and hope.
Your voice and words have power—the power of showing people that they’re not alone and the power of increasing awareness, education and hope.
Tafasitamab achieved a real-world overall response rate of 73.5%, with a median duration of response of 9.6 months.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
Peter Voorhees, MD; Noopur Raje, MD; Saad Z. Usmani, MD, MBA, FACP, FASCO
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
Online resource for healthcare professionals, providing information, news & support relating to multiple myeloma
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…